A5000202300- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Melanoma and MAPK Pathways
- Cancer Treatment and Pharmacology
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Ear and Head Tumors
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Head and Neck Surgical Oncology
- Renal and related cancers
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Colorectal and Anal Carcinomas
- Brain Metastases and Treatment
- Health disparities and outcomes
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
The Netherlands Cancer Institute
2015-2025
Hospital General Universitari de Castelló
2024
Cancer Institute (WIA)
2023
Dutch Cancer Society
2015-2023
Princess Máxima Center
2019-2023
Leiden University Medical Center
2010-2022
University Medical Center Utrecht
2022
Erasmus MC - Sophia Children’s Hospital
2018-2022
Oncode Institute
2015-2020
Stichting Kinderoncologie Nederland
2019
Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deacetylase inhibitor) addition anti-PD-1 anti-CTLA-4 increased the IFN-γ and reduced tumor growth our murine melanoma model, rationalizing evaluation patients. To stratify patients into cohorts, we developed a baseline signature expression algorithm,...
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP improve the mCR rate. In Phase I dose-escalation part 12 patients, we showed that BV-DHAP is feasible. This II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three...
Patients with advanced penile squamous cell carcinoma have a poor prognosis (21% 2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (anti-PD-L1) in patients cancer, or without radiotherapy (RT).A single-center, nonrandomized phase II study two treatment arms was conducted 32 histologically confirmed cancer. All received (1,200 mg) once every 3 weeks. Twenty patients, who were expected to benefit RT for locoregional disease control, additional irradiation....
DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of DPYD variant alleles. However, the impact on treatment outcome these patients is largely unknown. Therefore, progression-free survival (PFS) and overall (OS) were compared between treated with a reduced dose wild-type controls receiving full retrospective matched-pair analysis.Data from prospective multicenter study (ClinicalTrials.gov identifier: NCT02324452) which received 25% (c.1236G>A c.2846A>T) or 50% (DPYD*2A...
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it largely unknown which patients ICI without could be an option and what benefit combination be. The adaptive BELLINI trial explored whether short induces immune activation (primary end point, twofold increase in CD8
LBA2 Background: Standard of care (SOC) for resectable, macroscopic stage III melanoma is therapeutic lymph node dissection (TLND) followed by adjuvant (adj) therapy with nivolumab (NIVO), pembrolizumab (PEM) or, in BRAFmut melanoma, dabrafenib + trametinib (DAB/TRAM). The recent phase 2 SWOG S1801 trial showed superior event-free survival (EFS) neoadjuvant (neoadj) adj PEM as compared to (estimated 2y-EFS 72% vs 49%). Additional trials demonstrated safety and high efficacy (77-80% 2y-EFS)...
Lynch syndrome increases the risk of gastric cancer (GC) and duodenal (DC), particularly in individuals with
Background To enhance risk stratification for Wilms tumour (WT) in a pre-operative chemotherapy setting, we explored the prognostic significance and optimal age cutoffs patients treated according to International Society of Paediatric Oncology Renal Tumour Study Group (SIOP-RTSG) protocols. Methods Patients(6 months-18 years) with unilateral WT were selected from prospective SIOP 93–01 2001 studies(1993–2016). Martingale residual analysis was used explore cutoffs. Outcome analyzed by uni-...
Recurrence rates after resection of colorectal cancer liver metastases (CRLM) are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is a promising prognostic biomarker. Focusing on patients resected CRLM, this study aimed to evaluate the association between detection postoperative ctDNA, pathologic response recurrence-free survival (RFS).Twenty-three were selected from an ongoing phase-3 trial who underwent RAS-mutant CRLM induction systemic treatment....
Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost a frequency treatment-related adverse events (TRAE) patients with BRAFV600-mutated melanoma. Short-term MAPKi induces T-cell infiltration is synergistic death-1 (PD-1) preclinical melanoma mouse model. The aim this phase 2b trial was to identify an optimal regimen short-term dabrafenib...
Objective In case of close or positive resection margins after oncological in head and neck surgery, additional treatment is necessary. When conventional options are exhausted, photodynamic therapy (PDT) can play a role achieving clear margins. The purpose the current study was to evaluate clinical benefit PDT as adjuvant next surgery with time interval between on survival outcomes also investigated. Study Design Retrospective cohort analysis. Methods Adjuvant performed patients malignancy...
<title>Abstract</title> <bold>Background: </bold>[<sup>18</sup>F]FDG PET/CT plays a crucial role in evaluating cancer patients and assessing treatment response, including BRAF-mutated melanoma. Metabolic tumor volume (MTV) total lesion glycolysis (TLG) have emerged as promising alternatives to standardized uptake value (SUV)-based measures for assessment. This study evaluates the predictive of SUVpeak, MTV, TLG predicting progression-free survival (PFS) advanced melanoma treated with...
While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their efficacy in high-grade serous ovarian (HGSOC) remains limited. Some patients, however, achieve lasting responses, emphasizing the need to understand how tumor microenvironment and molecular characteristics influence ICI response. The phase 2 Neo-Pembro study (NCT03126812) included 33 untreated stage IV HGSOC who were scheduled for 6 cycles of carboplatin-paclitaxel interval cytoreductive surgery....